GTG company logo final.png

Genetic Technologies


Genetic Technologies (ASX:GTG) Limited offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free